semaglutide pdufa intermediate P29-Arg34GLP-1(9-37)(Powder) _ 20381ES We're reading about FDA PDUFA

For patients with recurrent vulvovaginal candidiasis (four or more episodes annually), management should include: Microscopy and culture to identify the Candida species An induction-maintenance regimen (e.g., fluconazole 150mg every 72 hours for three doses, followed by weekly maintenance for up to six months) Thorough review of predisposing factors Management strategies for patients on Ozempic should include: Optimising glycaemic control as the cornerstone of preventionreviewing HbA1c targets and adjusting diabetes medications as needed Completing the full course of antifungal treatment even if symptoms resolve early Treating sexual partners if they have symptoms (though routine partner treatment is not necessary for uncomplicated cases) Reviewing and addressing modifiable risk factors Considering prophylactic antifungal therapy for patients with frequent recurrences Patients should be reassured that yeast infections, whilst uncomfortable, are treatable and that continuing Ozempic is appropriate provided diabetes control is optimised

Based on the literature review, primary adrenal insufficiency (PAI) has not been reported in PWS patients

Pharmacies must cease selling compounded semaglutide by April 22

Its efficacy in lowering blood glucose levels and aiding weight loss makes it a valuable option for many patients

With more than 1 billion people globally living with obesity, the addressable patient population is enormous